Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Century Therapeutics (IPSC) Tax Provisions (2022 - 2024)

Century Therapeutics (IPSC) has disclosed Tax Provisions for 3 consecutive years, with $907000.0 as the latest value for Q4 2024.

  • On a quarterly basis, Tax Provisions rose 204.37% to $907000.0 in Q4 2024 year-over-year; TTM through Dec 2024 was $922000.0, a 50.98% decrease, with the full-year FY2024 number at $921000.0, down 51.04% from a year prior.
  • Tax Provisions was $907000.0 for Q4 2024 at Century Therapeutics, up from -$8000.0 in the prior quarter.
  • In the past five years, Tax Provisions ranged from a high of $1.2 million in Q1 2023 to a low of -$869000.0 in Q4 2023.
  • A 3-year average of $240750.0 and a median of $23500.0 in 2022 define the central range for Tax Provisions.
  • Biggest YoY gain for Tax Provisions was 7450.0% in 2023; the steepest drop was 3318.52% in 2023.
  • Century Therapeutics' Tax Provisions stood at $27000.0 in 2022, then tumbled by 3318.52% to -$869000.0 in 2023, then soared by 204.37% to $907000.0 in 2024.
  • Per Business Quant, the three most recent readings for IPSC's Tax Provisions are $907000.0 (Q4 2024), -$8000.0 (Q3 2024), and $22000.0 (Q2 2024).